Roivant Sciences ROIV
NASDAQ ROIV
$41.90 +0.71 (+1.72%)
As of: Nov 11, 2026 · 11:33 AM EST

Roivant Sciences (ROIV) Non-Current Deferred Revenue (2022)

Updated

Roivant Sciences (ROIV) reported Non-Current Deffered Revenue of $11.9 million for fiscal Q2 2023 (quarter ended Sep 30, 2022), down 9.5% from the prior quarter.

Analysis

Roivant Sciences (ROIV) Non-Current Deferred Revenue (2022) Analysis & Trends

At the end of FY2022 (ended Mar 31, 2022), Roivant Sciences posted Non-Current Deffered Revenue of $13.74 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Roivant Sciences 29.81 Bn 13.51 Bn 31.77 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2022 11.90 Mn
Jun 30, 2022 13.15 Mn
Mar 31, 2022 13.74 Mn
API Access

Roivant Sciences Non-Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=ROIV&period=max&api_key=YOUR_API_KEY